RxDoctor Payments Data

Deborah Koehn, MD

Internal Medicine · Richmond, VANPI 1942347646

Payments from drug & device makers

$1,420in general payments, 2019–2025

Across 12 payments — averaging $118.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$994
  • Amgen$121
  • Aerie Pharmaceuticals, Inc.$95
  • Regeneron$76
  • Boehringer Ingelheim$46
  • Novo Nordisk$39
  • plus $48 from 2 others

What the payments were for

  • Travel & lodging$96468%
  • Food & beverage$45632%

General payments by program year

19
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,420 in reported general payments places this provider in the 80th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$16,869
Medicare patients
139
Services billed
176

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EvkeezaEvinacumab-Dgnb14$395,376
Repatha SureclickEvolocumab383$213,757
MounjaroTirzepatide48$55,816
Repatha PushtronexEvolocumab67$39,700
Praluent PenAlirocumab61$28,892
TrulicityDulaglutide19$27,252
OzempicSemaglutide25$26,098
JardianceEmpagliflozin15$22,494
EliquisApixaban13$13,642
VascepaIcosapent Ethyl24$11,836
Atorvastatin Calcium335$3,350
Ezetimibe140$3,025
Humalog Kwikpen U-100Insulin Lispro15$2,578
Rosuvastatin Calcium115$1,413
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,231

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$39$26,09825 claims
Boehringer IngelheimJardiance$46$22,49415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →